33 completed, 11 terminated, 8 active not recruiting, 5 recruiting. 62 Phase 1, 20 Phase 2.
Follow Abiraterone Acetate: new trials by email Literature Review of Abiraterone Acetate trials Research Report on Abiraterone Acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer QLC5508, abiraterone acetate, enzalutamide - Advanced Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 212 | 2025-11-05 | 2026-06-02 |
| Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer QLH12016, abiraterone acetate, enzalutamide - Prostatic Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 50 | 2025-10-01 | 2025-08-05 |
| M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) M9466, Tuvusertib, Abiraterone acetate - Advanced Solid Tumor | Phase 1 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 60 | 2024-08-07 | 2026-09-09 |
| A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer Tinengotinib, abiraterone acetate with prednisone, Enzalutamide - Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2024-06-04 | 2026-06-25 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects SOL-804-F, Zytiga - Prostate Cancer | Phase 1 | Completed | Bukwang Pharmaceutical | 48 | 2023-08-10 | 2024-02-05 |
| Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) HRS-5041, Docetaxel injection, Abiraterone acetate tablets - Advanced Prostate Cancer | Phase 1 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2023-08-03 | 2026-08-31 |
| A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer Pasritamig, Cetrelimab, Cabazitaxel - Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer | Phase 1 | Recruiting | Janssen Research & Development, LLC | 300 | 2023-04-26 | 2026-09-25 |
| Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log - Prostate Cancer, Prostate Adenocarcinoma | Phase 1 | Terminated | University of Chicago | 50 | 2023-01-24 | 2025-10-03 |
| Phase 1 Study of ATRS-2002 in Healthy Male Adults Abiraterone Acetate - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Withdrawn | Syneos Health | 2022-09-01 | 2023-04-28 | |
| To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer TQB3823 tablets, Abiraterone acetate tablets, prednisone acetate tablets - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 39 | 2022-08-25 | 2023-11-03 |
| Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer AZD5305, Enzalutamide, Abiraterone Acetate - Metastatic Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 174 | 2022-06-02 | 2026-08-26 |
| Study of ORIC-944 in Patients With Metastatic Prostate Cancer ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets - Metastatic Prostate Cancer | Phase 1 | Recruiting | ORIC Pharmaceuticals | 275 | 2022-06-01 | 2026-07-09 |
| A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) EPI-7386, Abiraterone Acetate, Prednisone or Prednisolone - Prostatic Neoplasms | Phase 1 | Terminated | Janssen Research & Development, LLC | 3 | 2022-03-23 | 2025-02-03 |
| Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients Abiraterone Acetate - Prostate Cancer, Metastatic Cancer | Phase 1 | Unknown | National University Hospital, Singapore | 10 | 2021-11-30 | 2024-01-08 |
| A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone) - Prostate Cancer Metastatic | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 164 | 2021-09-02 | 2026-08-18 |
| A Study of CC-90011 and Comparators in Participants With Prostate Cancer CC-90011, Abiraterone, Prednisone - Prostatic Neoplasms | Phase 1 | Completed | Celgene | 6 | 2021-07-28 | 2023-09-13 |
| ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer ARX517, Apalutamide, Abiraterone acetate - Metastatic Prostate Cancer | Phase 1 | Active not recruiting | Janssen Research & Development, LLC | 183 | 2021-05-03 | 2026-09-28 |
| A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers BR9004, BR9004-1 - Prostate Cancer | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 40 | 2021-04-15 | 2021-07-22 |
| Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) Cabozantinib, Nivolumab, Abiraterone acetate - Metastatic Hormone Refractory Prostate Cancer | Phase 1 | Completed | Washington University School of Medicine | 18 | 2021-02-19 | 2025-11-12 |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer Relugolix, Abiraterone, Prednisone - Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 48 | 2021-02-18 | 2025-08-17 |
Showing 20 of 62. Sign in to see all of them.
Prostatic Neoplasms (37) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Genital Neoplasms, Male (2) · Urogenital Neoplasms (2) · Adenocarcinoma (1) · Adrenal Hyperplasia, Congenital (1) · Colorectal Neoplasms (1) · Congenital adrenal hyperplasia due to 21 hydroxylase deficiency (1) · Genital Diseases, Male (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms by Site (1) · Ovarian Neoplasms (1) · Prostatic Diseases (1)
Janssen Research & Development, LLC (14) · Cougar Biotechnology, Inc. (3) · Aragon Pharmaceuticals, Inc. (2) · AstraZeneca (2) · Qilu Pharmaceutical Co., Ltd. (2) · Arno Therapeutics (1) · Astex Pharmaceuticals, Inc. (1) · Boryung Pharmaceutical Co., Ltd (1) · Bukwang Pharmaceutical (1) · Cancer Research UK (1) · Celgene (1) · CellCentric Ltd. (1) · Charles Ryan (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Dana-Farber Cancer Institute (1)
United States (39) · United Kingdom (14) · Spain (8) · Canada (7) · Australia (4) · Belgium (4) · China (4) · Netherlands (4) · France (3) · South Korea (3) · Japan (2) · Sweden (2) · Georgia (1) · Italy (1) · Moldova (1)
Cougar Biotechnology, Inc. Clinical Trial (2) · An-Hye Kim (1) · Ana Molina, MD (1) · Charles Ryan, MD (1) · Christopher Sweeney, MBBS (1) · Daniel Spratt, M.D. (1) · David Burger, PhD (1)
PMID 22747660, PMID 24374856, PMID 24787968, PMID 28039155, PMID 28178640, PMID 28314838, PMID 33754187, PMID 35397952, PMID 36125208, PMID 36826464, PMID 37060432, PMID 37940446, PMID 38436924, PMID 38926066, PMID 39172730, PMID 40016438, PMID 40180682, PMID 40796417, PMID 42070919
2023 (3), 2016 (2), 2019 (2), 2014 (1), P30CA069533 (1), U01HD083493 (1)